Paliperidone

Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder

SAN DIEGO, April 1 /PRNewswire/ -- Patients with schizoaffective disorder who received paliperidone extended release tablets (paliperidone ER) for six weeks showed significant improvement in a broad range of schizoaffective symptoms, according to a new study presented today at the 12th Internation...

Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate

TITUSVILLE, N.J., Oct. 29 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for paliperidone palmitate, an investigational, once-monthly atypical antipsy...

FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

...INVEGA SUSTENNA is available in milligrams (mg) of paliperidone palmitate in dose strengths of 39 mg, 78 mg, 117 m...equivalents (mg eq.) to paliperidone. Each dose of paliperidone palmitate is equivalent to a specific dose of paliperidone (39 mg, 78 mg, 117 mg, 156 mg and 234 mg of...

INVEGA(R) Approved as the First and Only Treatment for Schizoaffective Disorder

... antipsychotic medication, was first approved in the U.S. in December 2006. Janssen(R), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, markets paliperidone ER as INVEGA(R). It is approved for the acute and maintenance treatment of schizophrenia in the U.S. and for the treatment of schizophrenia in the E.U...

Effective new treatment for schizophrenia

... placebo-controlled trial. The authors studied paliperidone extended-release (ER) tablets, an investigational ...four treatments for 6 weeks: 6 mg or 12 mg/day of paliperidone ER, 10 mg/day of olanzapine (the active comparator...s: This double-blind study found that two doses of paliperidone extended release tablets were more effective than ...

INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia

...these are divided into both positive and negative symptoms. References (1) Kramer M, Simpson G, Kushner S et al., Long-term safety/tolerability of paliperidone extended-release tablets: 52-week, open-label, extension phase of a schizophrenia symptom recurrence prevention study, December 2007 ...

INVEGA Receives Marketing Authorization In EU For Treatment Of Schizophrenia

...ase tablets), an atypical antipsychotic medication for the treatment of schizophrenia. This once-daily medication is specifically designed to deliver paliperidone - the active ingredient in INVEGA - through the innovative osmotic delivery system (OROS(R)). In clinical trials, INVEGA demonstrated significant effi...

INVEGA(TM) Gets Marketing Authority from EU to Treat Schizophrenia

...ase tablets), an atypical antipsychotic medication for the treatment of schizophrenia. This once-daily medication is specifically designed to deliver paliperidone - the active ingredient in INVEGA - through the innovative osmotic delivery system (OROS(R)). In clinical trials, INVEGA demonstrated signific...

Paliperidone in Medical Technology

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)

TITUSVILLE, N.J., Feb. 6 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) today announced that the company has submitted multiple applications to the U.S. Food and Drug Administration (FDA) which, if approved, would broaden treatment options for...

Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder

First Clinical Study of Paliperidone ER in this Under-Studied Condition SAN DIEGO, Nov. 1 /PRNewswire/ -- Patients with schizoaffective disorder receiving paliperidone extended release tablets (paliperidone ER) for six weeks showed a significant improvement in their symptoms, according to a ne...

Blood Levels of Paliperidone Extended-Release Tablets are Not Increased by Common Antidepressant

Study shows paroxetine produced no significant drug interaction with paliperidone ER SAN DIEGO, May 22, 2007 /PRNewswire/ -- After administration of paliperidone extended-release (ER) tablets, blood levels of the drug were not affected when given with a common antidepressant, according to new data...

Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

... SUSTENNA(TM) is available in milligrams (mg) of paliperidone palmitate in dose strengths of 39 mg, 78 mg, 117 m...equivalents (mg eq.) to paliperidone. Each dose of paliperidone palmitate is equivalent to a specific dose of paliperidone (39 mg, 78 mg, 117 mg, 156 mg and 234 mg of...

Paliperidone in Biological Technology

Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia

Results of Two Trials Identify Potential Initiation Dosing Regimen TITUSVILLE, N.J., Dec. 10 /PRNewswire/ -- Paliperidone palmitate, an investigational long-acting therapy (LAT) demonstrated statistically significant symptom control compared with placebo according to the results of a 13-w...

Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources

Separate Analysis Suggests Paliperidone ER May Impact Employment Status WASHINGTON, May 7 /PRNewswire-FirstCall/ -- Patients receiving paliperidone extended-release tablets (paliperidone ER) spent significantly fewer days in the hospital, had significantly fewer emergency room and psychiatric-...

Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress

... U.S. Psychiatric and Mental Health Congress, which takes place October 11-14, 2007 in Kissimmee, FL. The poster, entitled "A Comparative Analysis of paliperidone ER and Quetiapine in Patients With a Recent, Acute Exacerbation of Schizophrenia" will be on display on Saturday, Oct. 13 from 2:15 p.m. to 5:15 p.m. ...